Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs. "We are excited to report these important clinical milestones that mark an impending data-rich period for Trevi's Haduvio," said Jennifer Good , President and CEO of Trevi Therapeutics. "Chronic cough in IPF is one of the most difficult-to-treat cough conditions where antifibrotics have not shown a benefit.
We believe the centrally and peripherally acting mechanism of Haduvio uniquely positions it to work throughout the cough reflex arc and potentially offer relief for this important unmet need in IPF." Clinical Updates The Phase 2b CORAL trial for the treatment of chronic cough in patients with IPF has enrolled 50% of the targeted study enrollment, which is the number of patients needed for the pre-specified sample size re-estimation (SSRE). The SSRE will be performed once the last of these patients complete the six weeks of treatment.
The outcome of t.